The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Ponsegromab for the Treatment of Cancer Cachexia
Open accessAbstract
BACKGROUND: Cachexia is a common complication of cancer and is associated with an increased risk of death. The level of growth differentiation factor 15 (GDF-15), a circulating cytokine, is elevated in cancer cachexia. In a small, open-label, phase 1b study involving patients with cancer cachexia, ponsegromab, a humanized monoclonal antibody inhibiting GDF-15, was associated with improved weight, appetite, and physical activity, along with suppressed serum GDF-15 levels. METHODS: In this phase 2, randomized, double-blind, 12-week trial, we assigned patients with cancer cachexia and an elevated serum GDF-15 level (≥1500 pg per milliliter) in a 1:1:1:1 ratio to receive ponsegromab at a dose of 100 mg, 200 mg, or 400 mg or to receive placebo, administered subcutaneously every 4 weeks for three doses. The primary end point was the change from baseline in body weight at 12 weeks. Key secondary end points were appetite and cachexia symptoms, digital measures of physical activity, and safety. RESULTS: A total of 187 patients underwent randomization. Of these patients, 40% had non-small-cell lung cancer, 32% had pancreatic cancer, and 29% had colorectal cancer. At 12 weeks, patients in the ponsegromab groups had significantly greater weight gain than those in the placebo group, with a median between-group difference of 1.22 kg (95% credible interval, 0.37 to 2.25) in the 100-mg group, 1.92 (95% credible interval, 0.92 to 2.97) in the 200-mg group, and 2.81 (95% credible interval, 1.55 to 4.08) in the 400-mg group. Improvements were observed across measures of appetite and cachexia symptoms, along with physical activity, in the 400-mg ponsegromab group relative to placebo. Adverse events of any cause were reported in 70% of the patients in the ponsegromab group and in 80% of those in the placebo group. CONCLUSIONS: Among patients with cancer cachexia and elevated GDF-15 levels, the inhibition of GDF-15 with ponsegromab resulted in increased weight gain and overall activity level and reduced cachexia symptoms, findings that confirmed the role of GDF-15 as a driver of cachexia. (Funded by Pfizer; ClinicalTrials.gov number, NCT05546476.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Power Analysis for the Behavioral Sciences (2nd ed.).
Lachenbruch, P. A., & Cohen, J. (1989) · Journal of the American Statistical Association · doi:10.2307/2290095 · Cited by 37,395
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Definition and classification of cancer cachexia: an international consensus
Fearon, K., Strasser, F., Anker, S. D., Bosaeus, I., Bruera, E., Fainsinger, R. L., Jatoi, A., Loprinzi, C., MacDonald, N., Mantovani, G., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70218-7 · Cited by 5,767
Nagueh, S. F., Smiseth, O. A., Appleton, C. P., Byrd, B. F., Dokainish, H., Edvardsen, T., Flachskampf, F. A., Gillebert, T. C., Klein, A. L., Lancellotti, P., et al. (2016) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2016.01.011 · Cited by 5,262
Mourtzakis, M., Prado, C. M. M., Lieffers, J. R., Reiman, T., McCargar, L. J., & Baracos, V. E. (2008) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h08-075 · Cited by 2,224
McMillan, D. C. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.08.003 · Cited by 1,398
Diagnostic Criteria for the Classification of Cancer-Associated Weight Loss
Martin, L., Senesse, P., Gioulbasanis, I., Antoun, S., Bozzetti, F., Deans, C., Strasser, F., Thoresen, L., Jagoe, R. T., Chasen, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.1894 · Cited by 798
The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL
Emmerson, P. J., Wang, F., Du, Y., Liu, Q., Pickard, R. T., Gonciarz, M. D., Coskun, T., Hamang, M. J., Sindelar, D. K., Ballman, K. K., et al. (2017) · Nature Medicine · doi:10.1038/nm.4393 · Cited by 675
Management of Cancer Cachexia: ASCO Guideline
Roeland, E. J., Bohlke, K., Baracos, V. E., Bruera, E., del Fabbro, E., Dixon, S., Fallon, M., Herrstedt, J., Lau, H., Platek, M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00611 · Cited by 644
Self-citationTemel, J. S., Abernethy, A. P., Currow, D. C., Friend, J., Duus, E. M., Yan, Y., & Fearon, K. C. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00558-6 · Cited by 639
Cited by
Vest, A. R., DiDomenico, R. J., Lichtenstein, L., Slater, T., Ekpo, E., Damluji, A. A., Bohula, E., Alviar, C. L., on behalf of the American Heart Association Acute Cardiac Care and General Cardiology Committee of the Council on Clinical Cardiology, & Council on Cardiovascular and Stroke Nursing (2026) · Circulation · doi:10.1161/cir.0000000000001405 · Cited by 15
Othman, N. O., Abdel-Aal, H. H., Elsherief, W. A., Farag, D. E., Hunter, C. N., & Alsirafy, S. A. (2025) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2025.7033 · Cited by 11
Metadata
- Authors
- Groarke, J. D., Crawford, J., Collins, S. M., Lubaczewski, S., Roeland, E. J., Naito, T., Hendifar, A. E., Fallon, M., Takayama, K., Asmis, T., Dunne, R. F., Karahanoglu, I., Northcott, C. A., Harrington, M. A., Rossulek, M., Qiu, R., & Saxena, A. R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-12-19
- Volume
- 391
- Issue
- 24
- Pages
- 2291-2303
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4402540592
- Cited by
- 319
- References
- 35
- FWCI
- 75.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ponsegromab for the Treatment of Cancer Cachexia. https://app.cochat.ai/papers/10.1056/nejmoa2409515
- The paper
- Groarke, J. D., Crawford, J., Collins, S. M., Lubaczewski, S., Roeland, E. J., Naito, T., Hendifar, A. E., Fallon, M., Takayama, K., Asmis, T., Dunne, R. F., Karahanoglu, I., Northcott, C. A., Harrington, M. A., Rossulek, M., Qiu, R., & Saxena, A. R. (2024). Ponsegromab for the Treatment of Cancer Cachexia. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2409515
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
